GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income Statement

GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income Statement

Income statement for 2024-01-01 through 2024-03-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

6,686,000,000 US dollars

Cost of goods sold

1,552,000,000 US dollars

Gross profit (calculated)

5,134,000,000 US dollars

Operating expenses (calculated)

9,456,000,000 US dollars

Operating (loss) income

negative 4,322,000,000 US dollars

Other income (expense), net (calculated)

negative 164,000,000 US dollars

(Loss) income before income taxes

negative 4,486,000,000 US dollars

Income tax (benefit) expense

negative 315,000,000 US dollars

Net (loss) income

negative 4,170,000,000 US dollars

Tecartus

100,000,000 US dollars

Yescarta

380,000,000 US dollars

Biktarvy

2,946,000,000 US dollars

Descovy

426,000,000 US dollars

Genvoya

403,000,000 US dollars

Odefsey

310,000,000 US dollars

Revenue share - Symtuza

141,000,000 US dollars

Other HIV

117,000,000 US dollars

Sofosbuvir/Velpatasvir

405,000,000 US dollars

Vemlidy

225,000,000 US dollars

Other Liver Disease

107,000,000 US dollars

Trodelvy

309,000,000 US dollars

AmBisome

144,000,000 US dollars

Other

80,000,000 US dollars

Royalty, contract and other revenues

39,000,000 US dollars

Veklury

555,000,000 US dollars

Selling, general and administrative expenses

1,375,000,000 US dollars

Acquired in-process research and development expenses

4,131,000,000 US dollars

Research and development expenses

1,520,000,000 US dollars

In-process research and development impairment

2,430,000,000 US dollars

Revenue before reconciliation (calculated)

6,687,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

• The amounts that make up net income come to −$4,171.00 M and net income is −$4,170.00 M; the $1.00 M difference is within the rounding of the filed amounts.